Document is current

Article History

Accepted: 19 December 2023

First Online: 27 January 2024

Declarations

:

: No funding was received for the preparation of this article.

: Steven Feldman has received research, speaking and/or consulting support from Eli Lilly and Company, GlaxoSmithKline/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, Leo Pharma, Mylan, Celgene, Ortho Dermatology, Menlo, Merck & Co, Qurient, Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Teladoc, BMS, Ono, Micreos, Eurofins, Informa, UpToDate, and the National Psoriasis Foundation. He is a founder and part owner of Causa Research and holds stock in Sensal Health. Jonathan Greenzaid has no conflicts of interest that are directly relevant to the content of this article.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: SF and JG contributed to the conception and design of the manuscript. JG collected, analyzed, and interpreted the data and drafted the manuscript. SF critically revised the manuscript and approved the final version to be published.